| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Oskar Jefsen, Kristoffer Højgaard, Sofie Laage Christiansen, Betina Elfving, David John Nutt, Gregers Wegener, Heidi Kaastrup Mülle. Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. Acta neuropsychiatrica. vol 31. issue 4. 2020-01-09. PMID:31106729. |
we investigated whether the administration of psilocybin had an antidepressant-like effect in a rat model of depression. |
2020-01-09 |
2023-08-13 |
rat |
| Martin K Madsen, Patrick M Fisher, Daniel Burmester, Agnete Dyssegaard, Dea S Stenbæk, Sara Kristiansen, Sys S Johansen, Sczabolz Lehel, Kristian Linnet, Claus Svarer, David Erritzoe, Brice Ozenne, Gitte M Knudse. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 44. issue 7. 2019-12-10. PMID:30685771. |
the main psychedelic component of magic mushrooms is psilocybin, which shows promise as a treatment for depression and other mental disorders. |
2019-12-10 |
2023-08-13 |
human |
| Haden A Geiger, Madeline G Wurst, R Nathan Daniel. DARK Classics in Chemical Neuroscience: Psilocybin. ACS chemical neuroscience. vol 9. issue 10. 2019-11-18. PMID:29956917. |
recently, however, preliminary studies with psilocybin have shown promise as potential for the treatment of obsessive compulsive disorder, alcohol addiction, tobacco addiction, and major depressive disorder, and the treatment of depression in terminally ill cancer patients. |
2019-11-18 |
2023-08-13 |
Not clear |
| Michael J Wasko, Paula A Witt-Enderby, Christopher K Surrat. DARK Classics in Chemical Neuroscience: Ibogaine. ACS chemical neuroscience. vol 9. issue 10. 2019-11-18. PMID:30216039. |
ibogaine analogs may also hold promise for treating anxiety and depression via the "psychedelic-assisted therapy" approach that employs hallucinogens including psilocybin and methylenedioxymethamphetamine ("ecstasy"). |
2019-11-18 |
2023-08-13 |
Not clear |
| Taylor Lyons, Robin L Carhart-Harri. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. Journal of psychopharmacology (Oxford, England). vol 32. issue 7. 2019-10-31. PMID:29338538. |
increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. |
2019-10-31 |
2023-08-13 |
human |
| D Erritzoe, L Roseman, M M Nour, K MacLean, M Kaelen, D J Nutt, R L Carhart-Harri. Effects of psilocybin therapy on personality structure. Acta psychiatrica Scandinavica. vol 138. issue 5. 2019-10-11. PMID:29923178. |
to explore whether psilocybin with psychological support modulates personality parameters in patients suffering from treatment-resistant depression (trd). |
2019-10-11 |
2023-08-13 |
Not clear |
| Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge, Lysia Demetriou, J Nienke Pannekoek, Matthew B Wall, Mark Tanner, Mendel Kaelen, John McGonigle, Kevin Murphy, Robert Leech, H Valerie Curran, David J Nut. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific reports. vol 7. issue 1. 2019-07-01. PMID:29030624. |
psilocybin for treatment-resistant depression: fmri-measured brain mechanisms. |
2019-07-01 |
2023-08-13 |
Not clear |
| Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge, Lysia Demetriou, J Nienke Pannekoek, Matthew B Wall, Mark Tanner, Mendel Kaelen, John McGonigle, Kevin Murphy, Robert Leech, H Valerie Curran, David J Nut. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific reports. vol 7. issue 1. 2019-07-01. PMID:29030624. |
here, cerebral blood flow (cbf) and blood oxygen-level dependent (bold) resting-state functional connectivity (rsfc) were measured with functional magnetic resonance imaging (fmri) before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (trd). |
2019-07-01 |
2023-08-13 |
Not clear |
| Clinton E Cana. Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action. Handbook of experimental pharmacology. vol 252. 2019-06-13. PMID:29532180. |
recent, well-controlled - albeit small-scale - clinical trials show that serotonergic psychedelics, including psilocybin and lysergic acid diethylamide, possess great promise for treating psychiatric disorders, including treatment-resistant depression. |
2019-06-13 |
2023-08-13 |
Not clear |
| Phil Cowe. Altered states: psilocybin for treatment-resistant depression. The lancet. Psychiatry. vol 3. issue 7. 2019-05-30. PMID:27210032. |
altered states: psilocybin for treatment-resistant depression. |
2019-05-30 |
2023-08-13 |
Not clear |
| Leor Roseman, Lysia Demetriou, Matthew B Wall, David J Nutt, Robin L Carhart-Harri. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology. vol 142. 2019-02-20. PMID:29288686. |
increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. |
2019-02-20 |
2023-08-13 |
Not clear |
| Leor Roseman, Lysia Demetriou, Matthew B Wall, David J Nutt, Robin L Carhart-Harri. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology. vol 142. 2019-02-20. PMID:29288686. |
recent evidence indicates that psilocybin with psychological support may be effective for treating depression. |
2019-02-20 |
2023-08-13 |
Not clear |
| Janis Fricke, Claudius Lenz, Jonas Wick, Felix Blei, Dirk Hoffmeiste. Production Options for Psilocybin: Making of the Magic. Chemistry (Weinheim an der Bergstrasse, Germany). vol 25. issue 4. 2019-01-24. PMID:30011099. |
however, clinical trials have recognized psilocybin as a valuable candidate to be developed into a medication against depression and anxiety. |
2019-01-24 |
2023-08-13 |
Not clear |
| J B Stroud, T P Freeman, R Leech, C Hindocha, W Lawn, D J Nutt, H V Curran, R L Carhart-Harri. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology. vol 235. issue 2. 2018-12-31. PMID:29085980. |
psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. |
2018-12-31 |
2023-08-13 |
Not clear |
| R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling, J A Rickard, B Forbes, A Feilding, D Taylor, H V Curran, D J Nut. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. vol 235. issue 2. 2018-12-31. PMID:29119217. |
psilocybin with psychological support for treatment-resistant depression: six-month follow-up. |
2018-12-31 |
2023-08-13 |
Not clear |
| Andy Whelan, Mark I Johnso. Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role? Pain management. vol 8. issue 3. 2018-10-24. PMID:29722608. |
tentative evidence from a systematic review suggests that lsd (7 studies, 323 participants) and psilocybin (3 studies, 92 participants) may be beneficial for depression and anxiety associated with distress in life-threatening diseases. |
2018-10-24 |
2023-08-13 |
human |
| Michael P Bogenschutz, Stephen Ros. Therapeutic Applications of Classic Hallucinogens. Current topics in behavioral neurosciences. vol 36. 2018-09-20. PMID:28512684. |
to provide a clinical perspective, case summaries are provided of two individuals who received treatment in recent controlled trials of psilocybin: one being treated for alcoholism, the other suffering from anxiety and depression related to fear of death due to a cancer diagnosis. |
2018-09-20 |
2023-08-13 |
human |
| Rafael G Dos Santos, José Carlos Bouso, Miguel Ángel Alcázar-Córcoles, Jaime E C Halla. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert review of clinical pharmacology. vol 11. issue 9. 2018-09-17. PMID:30102078. |
expert commentary: psilocybin and lsd reduced anxiety and depression in cancer patients and symptoms of alcohol and tobacco dependence, and ayahuasca reduced depression symptoms in treatment-resistant depression. |
2018-09-17 |
2023-08-13 |
Not clear |
| Facundo Carrillo, Mariano Sigman, Diego Fernández Slezak, Philip Ashton, Lily Fitzgerald, Jack Stroud, David J Nutt, Robin L Carhart-Harri. Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. Journal of affective disorders. vol 230. 2018-09-04. PMID:29407543. |
natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. |
2018-09-04 |
2023-08-13 |
Not clear |
| John D McCorvy, Reid Hj Olsen, Bryan L Rot. Psilocybin for depression and anxiety associated with life-threatening illnesses. Journal of psychopharmacology (Oxford, England). vol 30. issue 12. 2018-08-24. PMID:27909171. |
psilocybin for depression and anxiety associated with life-threatening illnesses. |
2018-08-24 |
2023-08-13 |
Not clear |